{"transactions":[{"id":750062,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-06-04T20:09:59.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":false,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001062822-26-000102","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000102/form4.xml","form_type":"4"}},{"id":750061,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-04T20:09:59.000Z","date":"2026-06-03","kind":"exercise","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1995498,"source":{"system":"sec-edgar","filing":"0001062822-26-000102","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000102/form4.xml","form_type":"4"}},{"id":794403,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T20:09:37.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":43478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":43478,"derivative":{"exercise_price":1.61,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":43478},"source":{"system":"sec-edgar","filing":"0001062822-26-000067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000067/form4.xml","form_type":"4"}},{"id":794402,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:09:37.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":35714,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001062822-26-000067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000067/form4.xml","form_type":"4"}},{"id":878062,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-27T13:33:21.000Z","date":"2026-02-25","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":1.49,"value":2980.0,"ownership":{"direct":true},"balance_after":1906186,"source":{"system":"sec-edgar","filing":"0001062822-26-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000033/form4.xml","form_type":"4"}},{"id":882470,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-25T12:00:27.000Z","date":"2026-02-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.47,"value":147000.0,"ownership":{"direct":true},"balance_after":1904186,"source":{"system":"sec-edgar","filing":"0001062822-26-000032","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000032/form4.xml","form_type":"4"}},{"id":888826,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-23T12:49:43.000Z","date":"2026-02-20","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.4779,"value":147790.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1804186,"source":{"system":"sec-edgar","filing":"0001062822-26-000031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000031/form4.xml","form_type":"4"}},{"id":888825,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-23T12:49:43.000Z","date":"2026-02-19","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.4393,"value":71965.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1704186,"source":{"system":"sec-edgar","filing":"0001062822-26-000031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000031/form4.xml","form_type":"4"}},{"id":898143,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-18T21:30:52.000Z","date":"2026-02-18","kind":"purchase","planned":false,"acquired":true,"shares":133688,"price":1.32,"value":176468.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.315 to $1.32 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1654186,"source":{"system":"sec-edgar","filing":"0001062822-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000029/form4.xml","form_type":"4"}},{"id":898142,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-18T21:30:52.000Z","date":"2026-02-17","kind":"purchase","planned":false,"acquired":true,"shares":76857,"price":1.3082,"value":100544.3274,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.295 to $1.31 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1520498,"source":{"system":"sec-edgar","filing":"0001062822-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000029/form4.xml","form_type":"4"}},{"id":898141,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-18T21:30:52.000Z","date":"2026-02-13","kind":"purchase","planned":false,"acquired":true,"shares":57952,"price":1.3093,"value":75876.5536,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.31 per share.  The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":1443641,"source":{"system":"sec-edgar","filing":"0001062822-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000029/form4.xml","form_type":"4"}},{"id":916461,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-02-06T22:35:54.000Z","date":"2025-12-11","kind":"other","planned":false,"acquired":false,"shares":1575008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":7.35,"exercise_date":"2022-06-22","expiration_date":"2025-12-31","underlying":"Common Stock","underlying_shares":1575008},"source":{"system":"sec-edgar","filing":"0001193125-26-041456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000119312526041456/ownership.xml","form_type":"4"}},{"id":916460,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T22:35:54.000Z","date":"2025-12-11","kind":"other","planned":false,"acquired":true,"shares":1575008,"price":7.35,"value":11576308.8,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":10825013,"source":{"system":"sec-edgar","filing":"0001193125-26-041456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000119312526041456/ownership.xml","form_type":"4"}},{"id":919977,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":367145.12,"price":65,"value":23864432.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the \"Preferred Purchase Agreement\") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the \"Preferred Stock\") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":367145.12,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}},{"id":919976,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"purchase","planned":false,"acquired":true,"shares":1538462,"price":1.3,"value":2000000.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are directly held by Avicenna Life Sci Master Fund LP"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":1538462,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}},{"id":919975,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":3846154,"price":1.3,"value":5000000.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the \"Common Stock\") of the Issuer at a price of $1.30 per share (the \"Purchase Price\"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by Invus Public Equities, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7362368,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}},{"id":919974,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":1,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":2,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37420,"kind":"person","name":"Artal Participations S.a r.l.","position":4,"cik":"0002048403","reported_name":"Artal Participations S.a r.l.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37421,"kind":"person","name":"Artal International S.C.A.","position":5,"cik":"0001218180","reported_name":"Artal International S.C.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37422,"kind":"person","name":"Artal International Management S.A.","position":6,"cik":"0001522131","reported_name":"Artal International Management S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37423,"kind":"person","name":"Artal Group S.A.","position":7,"cik":"0001053906","reported_name":"Artal Group S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37424,"kind":"person","name":"Westend S.A.","position":8,"cik":"0001283968","reported_name":"Westend S.A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37425,"kind":"person","name":"Stichting Administratiekantoor Westend","position":9,"cik":"0001460840","reported_name":"Stichting Administratiekantoor Westend","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:25:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":18553846,"price":1.3,"value":24119999.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the \"Common Stock\") of the Issuer at a price of $1.30 per share (the \"Purchase Price\"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by Artal Participations S.a r.l."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the \"Stichting\"). Mr. Amaury Wittouck is the sole member of the board of the Stichting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":154734327,"source":{"system":"sec-edgar","filing":"0001193125-26-037644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526037644/ownership.xml","form_type":"4"}},{"id":1125928,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-06-03T20:20:14.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":89312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":89312,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":89312},"source":{"system":"sec-edgar","filing":"0001127602-25-016458","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225016458/form4.xml","form_type":"4"}},{"id":1125927,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-03T20:20:14.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":103806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":103806,"derivative":{"exercise_price":0.6216,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":103806},"source":{"system":"sec-edgar","filing":"0001127602-25-016458","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225016458/form4.xml","form_type":"4"}},{"id":1151234,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-13T21:48:38.000Z","date":"2025-05-13","kind":"exercise","planned":false,"acquired":false,"shares":36810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":36810},"source":{"system":"sec-edgar","filing":"0001127602-25-014139","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225014139/form4.xml","form_type":"4"}},{"id":1151233,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-13T21:48:38.000Z","date":"2025-05-13","kind":"exercise","planned":false,"acquired":true,"shares":36810,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1385689,"source":{"system":"sec-edgar","filing":"0001127602-25-014139","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225014139/form4.xml","form_type":"4"}},{"id":1334379,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T21:39:58.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":1600000,"price":41.65,"value":66640000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":9250005,"source":{"system":"sec-edgar","filing":"0000950170-24-135847","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024135847/ownership.xml","form_type":"4"}},{"id":1349869,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:31:00.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":149,"price":40.98,"value":6106.02,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":10850005,"source":{"system":"sec-edgar","filing":"0000950170-24-131539","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024131539/ownership.xml","form_type":"4"}},{"id":1349868,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:31:00.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":30683,"price":40.139,"value":1231584.937,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.960 to $40.940 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":10850154,"source":{"system":"sec-edgar","filing":"0000950170-24-131539","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024131539/ownership.xml","form_type":"4"}},{"id":1349867,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:31:00.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":126442,"price":39.5104,"value":4995773.9968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.960 to $39.955 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":10880837,"source":{"system":"sec-edgar","filing":"0000950170-24-131539","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024131539/ownership.xml","form_type":"4"}},{"id":1349866,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:31:00.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":43887,"price":38.4321,"value":1686669.5727,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.960 to $38.955 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":11007279,"source":{"system":"sec-edgar","filing":"0000950170-24-131539","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024131539/ownership.xml","form_type":"4"}},{"id":1349865,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:31:00.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":208272,"price":37.6311,"value":7837504.4592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.960 to $37.955 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":11051166,"source":{"system":"sec-edgar","filing":"0000950170-24-131539","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024131539/ownership.xml","form_type":"4"}},{"id":1437224,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-09T20:30:11.000Z","date":"2024-08-08","kind":"sale","planned":false,"acquired":false,"shares":260873,"price":0.1917,"value":50009.3541,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6317565,"source":{"system":"sec-edgar","filing":"0000950170-24-094800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024094800/ownership.xml","form_type":"4"}},{"id":1437223,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-09T20:30:11.000Z","date":"2024-08-07","kind":"sale","planned":false,"acquired":false,"shares":61488,"price":0.1821,"value":11196.9648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6578438,"source":{"system":"sec-edgar","filing":"0000950170-24-094800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024094800/ownership.xml","form_type":"4"}},{"id":1439032,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-07T20:30:11.000Z","date":"2024-08-06","kind":"sale","planned":false,"acquired":false,"shares":55732,"price":0.1828,"value":10187.8096,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1907 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6639926,"source":{"system":"sec-edgar","filing":"0000950170-24-092864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024092864/ownership.xml","form_type":"4"}},{"id":1439031,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-07T20:30:11.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":164523,"price":0.1884,"value":30996.1332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.187 to $0.1891 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6695658,"source":{"system":"sec-edgar","filing":"0000950170-24-092864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024092864/ownership.xml","form_type":"4"}},{"id":1441230,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:53:26.000Z","date":"2024-08-02","kind":"sale","planned":false,"acquired":false,"shares":286200,"price":0.2004,"value":57354.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.20 to $0.2025 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":6860181,"source":{"system":"sec-edgar","filing":"0000950170-24-090910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024090910/ownership.xml","form_type":"4"}},{"id":1441229,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:53:26.000Z","date":"2024-08-01","kind":"sale","planned":false,"acquired":false,"shares":63564,"price":0.2162,"value":13742.5368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.2185 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7146381,"source":{"system":"sec-edgar","filing":"0000950170-24-090910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024090910/ownership.xml","form_type":"4"}},{"id":1446491,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:16:35.000Z","date":"2024-07-30","kind":"sale","planned":false,"acquired":false,"shares":756835,"price":0.2209,"value":167184.8515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.24 per\nshare, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon\nrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7209945,"source":{"system":"sec-edgar","filing":"0000950170-24-088020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024088020/ownership.xml","form_type":"4"}},{"id":1446490,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:16:35.000Z","date":"2024-07-29","kind":"sale","planned":false,"acquired":false,"shares":363949,"price":0.2353,"value":85637.1997,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.23 to $0.241 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":7966780,"source":{"system":"sec-edgar","filing":"0000950170-24-088020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024088020/ownership.xml","form_type":"4"}},{"id":1446489,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":85166,"kind":"organization","name":"Invus Public Equities, L.P.","position":1,"cik":"0001340097","reported_name":"Invus Public Equities, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85167,"kind":"organization","name":"Invus Public Equities Advisors, LLC","position":2,"cik":"0001340096","reported_name":"Invus Public Equities Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67457,"kind":"organization","name":"Siren, L.L.C.","position":3,"cik":"0002005245","reported_name":"Siren, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67456,"kind":"organization","name":"Invus Global Management, LLC","position":4,"cik":"0002005369","reported_name":"Invus Global Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":5,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:16:35.000Z","date":"2024-07-26","kind":"sale","planned":false,"acquired":false,"shares":258335,"price":0.2417,"value":62439.5695,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.2451 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":8330729,"source":{"system":"sec-edgar","filing":"0000950170-24-088020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053890/000095017024088020/ownership.xml","form_type":"4"}},{"id":1519506,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-05-13T20:02:19.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":36810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":36810,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":36810},"source":{"system":"sec-edgar","filing":"0001127602-24-015079","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224015079/form4.xml","form_type":"4"}},{"id":1519505,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-13T20:02:19.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":44906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":44906,"derivative":{"exercise_price":1.79,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":44906},"source":{"system":"sec-edgar","filing":"0001127602-24-015079","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224015079/form4.xml","form_type":"4"}},{"id":1534027,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-04-29T20:17:58.000Z","date":"2024-04-28","kind":"exercise","planned":false,"acquired":false,"shares":8032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8032},"source":{"system":"sec-edgar","filing":"0001127602-24-013555","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224013555/form4.xml","form_type":"4"}},{"id":1534026,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-29T20:17:58.000Z","date":"2024-04-28","kind":"exercise","planned":false,"acquired":true,"shares":8032,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1348879,"source":{"system":"sec-edgar","filing":"0001127602-24-013555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224013555/form4.xml","form_type":"4"}},{"id":1761276,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-12T20:01:18.000Z","date":"2023-10-12","kind":"purchase","planned":false,"acquired":true,"shares":148820,"price":1.0335,"value":153805.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $1.02 to $1.07 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Debbane hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected."}],"balance_after":1340847,"source":{"system":"sec-edgar","filing":"0001127602-23-025798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223025798/form4.xml","form_type":"4"}},{"id":1761275,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-12T20:01:18.000Z","date":"2023-10-11","kind":"purchase","planned":false,"acquired":true,"shares":342874,"price":1.0814,"value":370783.9436,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.06 to $1.12 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Debbane hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":1192027,"source":{"system":"sec-edgar","filing":"0001127602-23-025798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223025798/form4.xml","form_type":"4"}},{"id":1761274,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-12T20:01:18.000Z","date":"2023-10-10","kind":"purchase","planned":false,"acquired":true,"shares":508306,"price":1.1398,"value":579367.1788,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.09 to $1.19 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Debbane hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected."}],"balance_after":849153,"source":{"system":"sec-edgar","filing":"0001127602-23-025798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223025798/form4.xml","form_type":"4"}},{"id":1883116,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-05-22T20:03:46.000Z","date":"2023-05-21","kind":"exercise","planned":false,"acquired":false,"shares":9302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9302},"source":{"system":"sec-edgar","filing":"0001127602-23-016431","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223016431/form4.xml","form_type":"4"}},{"id":1883115,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-22T20:03:46.000Z","date":"2023-05-21","kind":"exercise","planned":false,"acquired":true,"shares":9302,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":340847,"source":{"system":"sec-edgar","filing":"0001127602-23-016431","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223016431/form4.xml","form_type":"4"}},{"id":1897507,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2023-05-11T20:12:41.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":835,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":134387,"source":{"system":"sec-edgar","filing":"0001209191-23-028724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919123028724/doc4.xml","form_type":"4"}},{"id":1911575,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-28T20:22:49.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":12658,"derivative":{"exercise_price":2.36,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":12658},"source":{"system":"sec-edgar","filing":"0001127602-23-013782","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223013782/form4.xml","form_type":"4"}},{"id":1911574,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-04-28T20:22:49.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":8032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":8032,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8032},"source":{"system":"sec-edgar","filing":"0001127602-23-013782","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223013782/form4.xml","form_type":"4"}},{"id":1926139,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-05T20:05:12.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":2053,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":133552,"source":{"system":"sec-edgar","filing":"0001209191-23-023259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919123023259/doc4.xml","form_type":"4"}},{"id":2071195,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T21:22:35.000Z","date":"2023-01-02","kind":"grant","acquired":true,"shares":5067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":131499,"source":{"system":"sec-edgar","filing":"0001209191-23-000925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919123000925/doc4.xml","form_type":"4"}},{"id":2117104,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-15T22:26:14.000Z","date":"2022-11-10","kind":"purchase","acquired":true,"shares":75000,"price":4.2674,"value":320055.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.205 to $4.36, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":126432,"source":{"system":"sec-edgar","filing":"0001209191-22-057075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919122057075/doc4.xml","form_type":"4"}},{"id":2143238,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-05T21:27:59.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":4595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":51432,"source":{"system":"sec-edgar","filing":"0001209191-22-052828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919122052828/doc4.xml","form_type":"4"}},{"id":2191268,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":124790,"kind":"person","name":"Invus US Partners LLC","position":1,"cik":"0001839806","reported_name":"Invus US Partners LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107352,"kind":"organization","name":"Ulys, L.L.C.","position":2,"cik":"0001340098","reported_name":"Ulys, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T20:48:13.000Z","date":"2022-08-05","kind":"purchase","acquired":true,"shares":147390,"price":2.5,"value":368475.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the \"Issuer Common Stock\"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Invus US Partners LLC"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":5451204,"source":{"system":"sec-edgar","filing":"0000899243-22-028113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000089924322028113/doc4.xml","form_type":"4"}},{"id":2199349,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":124790,"kind":"person","name":"Invus US Partners LLC","position":1,"cik":"0001839806","reported_name":"Invus US Partners LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107352,"kind":"organization","name":"Ulys, L.L.C.","position":2,"cik":"0001340098","reported_name":"Ulys, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:15:28.000Z","date":"2022-08-01","kind":"purchase","acquired":true,"shares":982600,"price":2.5,"value":2456500.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 27, 2022, Invus US Partners LLC entered into a purchase agreement with the Issuer pursuant to which Invus US Partners LLC agreed to purchase 982,600 shares of common stock, $0.001 par value per share (the \"Issuer Common Stock\") of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Invus US Partners LLC"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":5303814,"source":{"system":"sec-edgar","filing":"0000899243-22-027157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000089924322027157/doc4.xml","form_type":"4"}},{"id":2199350,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-08-01T20:13:38.000Z","date":"2022-08-01","kind":"purchase","acquired":true,"shares":982600,"price":2.5,"value":2456500.0,"ownership":{"direct":false,"nature":"By Invus US Partners LLC"},"balance_after":5303814,"source":{"system":"sec-edgar","filing":"0001127602-22-020005","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222020005/form4.xml","form_type":"4"}},{"id":2213468,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T20:31:14.000Z","date":"2022-07-04","kind":"grant","acquired":true,"shares":2745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":46837,"source":{"system":"sec-edgar","filing":"0001209191-22-041132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919122041132/doc4.xml","form_type":"4"}},{"id":2260526,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-05-23T20:14:07.000Z","date":"2022-05-21","kind":"grant","acquired":true,"shares":9302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":9302,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9302},"source":{"system":"sec-edgar","filing":"0001127602-22-015368","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222015368/form4.xml","form_type":"4"}},{"id":2260525,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-23T20:14:07.000Z","date":"2022-05-21","kind":"grant","acquired":true,"shares":14402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":14402,"derivative":{"exercise_price":1.77,"expiration_date":"2032-05-21","underlying":"Common Stock","underlying_shares":14402},"source":{"system":"sec-edgar","filing":"0001127602-22-015368","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222015368/form4.xml","form_type":"4"}},{"id":2286816,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-05-02T20:14:26.000Z","date":"2022-04-30","kind":"exercise","acquired":false,"shares":4024,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4024},"source":{"system":"sec-edgar","filing":"0001127602-22-012827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222012827/form4.xml","form_type":"4"}},{"id":2286815,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-02T20:14:26.000Z","date":"2022-04-30","kind":"exercise","acquired":true,"shares":4024,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":331545,"source":{"system":"sec-edgar","filing":"0001127602-22-012827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222012827/form4.xml","form_type":"4"}},{"id":2303053,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-06T20:15:47.000Z","date":"2022-04-04","kind":"grant","acquired":true,"shares":1797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":44092,"source":{"system":"sec-edgar","filing":"0001209191-22-023464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919122023464/doc4.xml","form_type":"4"}},{"id":2446351,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T21:16:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":1179,"price":15.9,"value":18746.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":42295,"source":{"system":"sec-edgar","filing":"0001209191-22-001654","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919122001654/doc4.xml","form_type":"4"}},{"id":2547645,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T20:07:40.000Z","date":"2021-10-04","kind":"grant","acquired":true,"shares":998,"price":18.78,"value":18742.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":41116,"source":{"system":"sec-edgar","filing":"0001209191-21-059807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919121059807/doc4.xml","form_type":"4"}},{"id":2640189,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-07T20:20:44.000Z","date":"2021-07-05","kind":"grant","acquired":true,"shares":523,"price":35.84,"value":18744.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":40118,"source":{"system":"sec-edgar","filing":"0001209191-21-045786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919121045786/doc4.xml","form_type":"4"}},{"id":2733359,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-03T21:03:50.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":6475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":6475,"derivative":{"exercise_price":5.04,"expiration_date":"2031-04-30","underlying":"Common Stock","underlying_shares":6475},"source":{"system":"sec-edgar","filing":"0001127602-21-014963","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221014963/form4.xml","form_type":"4"}},{"id":2733358,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-05-03T21:03:50.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":4024,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":4024,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4024},"source":{"system":"sec-edgar","filing":"0001127602-21-014963","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221014963/form4.xml","form_type":"4"}},{"id":2738788,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-04-27T20:47:16.000Z","date":"2021-04-24","kind":"exercise","acquired":false,"shares":10638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":10638},"source":{"system":"sec-edgar","filing":"0001127602-21-014519","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221014519/form4.xml","form_type":"4"}},{"id":2738787,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-27T20:47:16.000Z","date":"2021-04-24","kind":"exercise","acquired":true,"shares":10638,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":327521,"source":{"system":"sec-edgar","filing":"0001127602-21-014519","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221014519/form4.xml","form_type":"4"}},{"id":2755019,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-07T20:17:00.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":609,"price":30.77,"value":18738.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":39595,"source":{"system":"sec-edgar","filing":"0001209191-21-025862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919121025862/doc4.xml","form_type":"4"}},{"id":2917864,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T21:16:38.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":38986,"source":{"system":"sec-edgar","filing":"0001209191-21-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919121002025/doc4.xml","form_type":"4"}},{"id":3020393,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T21:47:49.000Z","date":"2020-09-28","kind":"grant","acquired":true,"shares":996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":38262,"source":{"system":"sec-edgar","filing":"0001209191-20-052484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919120052484/doc4.xml","form_type":"4"}},{"id":3095971,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T20:09:09.000Z","date":"2020-06-29","kind":"grant","acquired":true,"shares":740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":37266,"source":{"system":"sec-edgar","filing":"0001209191-20-039712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919120039712/doc4.xml","form_type":"4"}},{"id":3169350,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2020-04-27T20:45:43.000Z","date":"2020-04-26","kind":"exercise","acquired":false,"shares":3466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3466},"source":{"system":"sec-edgar","filing":"0001127602-20-014563","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220014563/form4.xml","form_type":"4"}},{"id":3169349,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2020-04-27T20:45:43.000Z","date":"2020-04-24","kind":"grant","acquired":true,"shares":10638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":10638,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":10638},"source":{"system":"sec-edgar","filing":"0001127602-20-014563","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220014563/form4.xml","form_type":"4"}},{"id":3169348,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-27T20:45:43.000Z","date":"2020-04-24","kind":"grant","acquired":true,"shares":18115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date."}],"balance_after":18115,"derivative":{"exercise_price":1.86,"expiration_date":"2030-04-24","underlying":"Common Stock","underlying_shares":18115},"source":{"system":"sec-edgar","filing":"0001127602-20-014563","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220014563/form4.xml","form_type":"4"}},{"id":3169347,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-04-27T20:45:43.000Z","date":"2020-04-26","kind":"exercise","acquired":true,"shares":3466,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":316883,"source":{"system":"sec-edgar","filing":"0001127602-20-014563","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220014563/form4.xml","form_type":"4"}},{"id":3190115,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-01T20:16:09.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":1128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":36526,"source":{"system":"sec-edgar","filing":"0001209191-20-022098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919120022098/doc4.xml","form_type":"4"}},{"id":3328380,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-02T21:11:49.000Z","date":"2019-12-30","kind":"grant","acquired":true,"shares":469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":35398,"source":{"system":"sec-edgar","filing":"0001209191-20-000255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919120000255/doc4.xml","form_type":"4"}},{"id":3402147,"issuer":{"id":6479,"kind":"organization","name":"WW INTERNATIONAL, INC.","symbol":"WW"},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-02T20:59:57.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares listed represent shares of Common Stock subject to transfer restrictions."}],"balance_after":34929,"source":{"system":"sec-edgar","filing":"0001209191-19-051799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105319/000120919119051799/doc4.xml","form_type":"4"}},{"id":3412822,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":3400,"price":2.8,"value":9520.0,"ownership":{"direct":true},"balance_after":313417,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412821,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":7500,"price":2.79,"value":20925.0,"ownership":{"direct":true},"balance_after":310017,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412820,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":3900,"price":2.78,"value":10842.0,"ownership":{"direct":true},"balance_after":302517,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412819,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":12400,"price":2.77,"value":34348.0,"ownership":{"direct":true},"balance_after":298617,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412818,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":4500,"price":2.76,"value":12420.0,"ownership":{"direct":true},"balance_after":286217,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412817,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":6853,"price":2.75,"value":18845.75,"ownership":{"direct":true},"balance_after":281717,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412816,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":1900,"price":2.74,"value":5206.0,"ownership":{"direct":true},"balance_after":274864,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412815,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":11100,"price":2.73,"value":30303.0,"ownership":{"direct":true},"balance_after":272964,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412814,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":8082,"price":2.72,"value":21983.04,"ownership":{"direct":true},"balance_after":261864,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412813,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":6443,"price":2.71,"value":17460.53,"ownership":{"direct":true},"balance_after":253782,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412812,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":400,"price":2.7,"value":1080.0,"ownership":{"direct":true},"balance_after":247339,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412811,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":500,"price":2.69,"value":1345.0,"ownership":{"direct":true},"balance_after":246939,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412810,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":1300,"price":2.68,"value":3484.0,"ownership":{"direct":true},"balance_after":246439,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412809,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":4600,"price":2.67,"value":12282.0,"ownership":{"direct":true},"balance_after":245139,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412808,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":1100,"price":2.66,"value":2926.0,"ownership":{"direct":true},"balance_after":240539,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412807,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":2100,"price":2.64,"value":5544.0,"ownership":{"direct":true},"balance_after":239439,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412806,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":4800,"price":2.63,"value":12624.0,"ownership":{"direct":true},"balance_after":237339,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412805,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":3110,"price":2.62,"value":8148.2,"ownership":{"direct":true},"balance_after":232539,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412804,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":5795,"price":2.61,"value":15124.95,"ownership":{"direct":true},"balance_after":229429,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412803,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":3990,"price":2.6,"value":10374.0,"ownership":{"direct":true},"balance_after":223634,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}},{"id":3412802,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":1,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-17T21:36:06.000Z","date":"2019-09-13","kind":"purchase","acquired":true,"shares":400,"price":2.47,"value":988.0,"ownership":{"direct":true},"balance_after":219644,"source":{"system":"sec-edgar","filing":"0001127602-19-028597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028597/form4.xml","form_type":"4"}}],"next_cursor":"2019-09-17T21:36:06.000000Z,3412802"}